tiprankstipranks
Trending News
More News >
Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
India Market
Advertisement

Sun Pharma Advanced Research Co. Ltd. (SPARC) Stock Statistics & Valuation Metrics

Compare
2 Followers

Total Valuation

Sun Pharma Advanced Research Co. Ltd. has a market cap or net worth of ₹45.94B. The enterprise value is ₹50.70B.
Market Cap₹45.94B
Enterprise Value₹50.70B

Share Statistics

Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding324,521,580
Owned by Insiders
Owned by Institutions

Financial Efficiency

Sun Pharma Advanced Research Co. Ltd.’s return on equity (ROE) is 1.58 and return on invested capital (ROIC) is -225.33%.
Return on Equity (ROE)1.58
Return on Assets (ROA)-1.02
Return on Invested Capital (ROIC)-225.33%
Return on Capital Employed (ROCE)7.18
Revenue Per Employee1.75M
Profits Per Employee-8.37M
Employee Count409
Asset Turnover0.21
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Sun Pharma Advanced Research Co. Ltd. is ―. Sun Pharma Advanced Research Co. Ltd.’s PEG ratio is 1.20.
PE Ratio
PS Ratio66.17
PB Ratio-21.89
Price to Fair Value-21.89
Price to FCF-12.81
Price to Operating Cash Flow0.00
PEG Ratio1.20

Income Statement

In the last 12 months, Sun Pharma Advanced Research Co. Ltd. had revenue of 717.70M and earned -3.43B in profits. Earnings per share was -10.55.
Revenue717.70M
Gross Profit486.50M
Operating Income-2.78B
Pretax Income-3.43B
Net Income-3.43B
EBITDA-3.23B
Earnings Per Share (EPS)-10.55

Cash Flow

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00

Dividends & Yields

Sun Pharma Advanced Research Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.53
52-Week Price Change-33.16%
50-Day Moving Average156.45
200-Day Moving Average167.41
Relative Strength Index (RSI)35.76
Average Volume (3m)29.94K

Important Dates

Sun Pharma Advanced Research Co. Ltd. upcoming earnings date is Nov 10, 2025, TBA (Confirmed).
Last Earnings DateAug 4, 2025
Next Earnings DateNov 10, 2025
Ex-Dividend Date

Financial Position

Sun Pharma Advanced Research Co. Ltd. as a current ratio of 0.07, with Debt / Equity ratio of -123.95%
Current Ratio0.07
Quick Ratio0.07
Debt to Market Cap0.05
Net Debt to EBITDA-0.83
Interest Coverage Ratio-30.75

Taxes

In the past 12 months, Sun Pharma Advanced Research Co. Ltd. has paid -2.70M in taxes.
Income Tax-2.70M
Effective Tax Rate<0.01

Enterprise Valuation

Sun Pharma Advanced Research Co. Ltd. EV to EBITDA ratio is -15.52, with an EV/FCF ratio of -13.53.
EV to Sales69.89
EV to EBITDA-15.52
EV to Free Cash Flow-13.53
EV to Operating Cash Flow-13.92

Balance Sheet

Sun Pharma Advanced Research Co. Ltd. has ₹19.60M in cash and marketable securities with ₹2.69B in debt, giving a net cash position of ₹2.67B billion.
Cash & Marketable Securities₹19.60M
Total Debt₹2.69B
Net Cash₹2.67B
Net Cash Per Share₹8.23
Tangible Book Value Per Share-₹8.34

Margins

Gross margin is 143.56%, with operating margin of -387.32%, and net profit margin of -477.23%.
Gross Margin143.56%
Operating Margin-387.32%
Pretax Margin-477.61%
Net Profit Margin-477.23%
EBITDA Margin-450.24%
EBIT Margin-467.51%

Analyst Forecast

The average price target for Sun Pharma Advanced Research Co. Ltd. is ₹150.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹150.00
Price Target Upside5.26% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-5.57%
EPS Growth Forecast23.03%

Scores

Smart ScoreN/A
AI Score40.6
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis